
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Indus is expected to experience strong growth in the coming years, with a focus on innovation and strategic acquisitions. The company's diverse portfolio and pipeline, including promising drugs such as TEV-53408 and Ecopipam, make it well-positioned for success. Teva's expertise in injectable products and plans for internal antibody development also bode well for future profitability and potential acquisitions.
Bears say
Teva Pharmaceutical Indus is facing significant challenges in the near future due to increasing competition in the generic drug market, potential loss of patent exclusivity for its leading drug Copaxone, and ongoing litigation and settlements related to opioid lawsuits. This, combined with its high debt levels and declining revenues, suggests a negative outlook for the company's financial performance in the coming years. Additionally, Teva's recent acquisition of businesses further adds to its debt burden and may hinder its ability to invest in research and development for innovative drugs. These factors could lead to a decline in Teva's market share and overall profitability.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares